A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial of the Safety, Efficacy, and Pharmacokinetics of XKDCT225 (Targeting Claudin18.2-CAR-T) Cell Injectionin Claudin18.2-positive Advanced Solid Tumors
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs XKDCT 225 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shenzhen Celconta Life Science
- 23 Jan 2025 New trial record